Wir sind mit live! Mehr erfahren
NMRD

Nemaura Medical, Inc. Common Stock
NMRD

Nicht mehr börsennotiert

NMRD wurde am 4. Januar 2024 von der Börse genommen.

Zurück zu den Rankings
 

Profil: Nemaura Medical Inc is a medical technology company developing sugarBEAT as a non-invasive, affordable, and flexible Continuous Glucose Monitor (CGM) designed for people with diabetes and pre-diabetics to manage their glucose levels. Insulin users can adjunctively use sugarBEAT when calibrated with a finger-stick glucose reading. SugarBEAT consists of a daily disposable adhesive skin patch connected to a rechargeable transmitter with an app displaying glucose readings at five-minute intervals for periods up to 24 hours.

Mitarbeiter: 38

Gesundheitswesen Medizinische Geräte und Verbrauchsmaterialien

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 0 %
Neutral 0 %
Negativ 0 %
Neutral
GlobeNewsWire
vor 2 Jahren
Important Update on Listing Status and Strategic Direction
Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs, is providing a crucial update regarding recent decisions that will impact Nemaura Medical's listing status on The Nasdaq Capital Market and our broader strategic direction.
Important Update on Listing Status and Strategic Direction
Neutral
GlobeNewsWire
vor 2 Jahren
Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision
Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce that the Nasdaq Hearings Panel granted the Company's request for continued listing pursuant to an exception, including certain interim milestones, that ultimately expires on April 1st, 2024, to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market.
Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision
Neutral
GlobeNewsWire
vor 2 Jahren
Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth
Loughborough, UK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce the execution of a strategic agreement for a $10 million credit facility which is expected to support the Company's strategic growth plans.
Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth
Positiv
Zacks Investment Research
vor 2 Jahren
Nemaura (NMRD) to Expand in UK With Metabolic Health Program
The latest program leverages Nemaura's (NMRD) world-first daily wear non-invasive CGM technology, providing individuals with real-time insights into their body's glucose dynamics.
Neutral
GlobeNewsWire
vor 2 Jahren
Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs
Company CEO to discuss development at 1pm EST on 15 th November 2023, at the Sidoti Virtual Investor Conference
Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs
Nachrichtenrankings ansehen
Kursdiagramme mit Lightweight Charts™ umgesetzt